AdvanSix 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- AdvanSix reported 3rd quarter 2026 sales of $431 million, up 15% year over year, driven by 17% favorable pricing and partially offset by a 2% decline in volume.
- Raw material pass-through pricing increased 10% and market-based pricing increased 7%; raw material costs were a $65 million adjusted EBITDA headwind, primarily from higher sulfur and benzene prices.
- Adjusted EBITDA was $15 million, down $10 million year over year, and adjusted earnings per share was a loss of $0.24, down $0.32 from the prior year.
- Cash flow from operations was $48 million, up $21 million year over year; CapEx was $18 million, down $8 million, and free cash flow was $30 million.
- Nylon resin sales increased 33% year over year, caprolactam sales were roughly flat, plant nutrients sales increased 8%, and chemical intermediate sales increased 24%.
- Working capital was a $24 million source of cash year to date, compared with a $56 million use of cash in the prior year period; year-to-date free cash flow was largely in line with last year, which included $26 million of insurance proceeds.
- AdvanSix was selected for $47 million in proposed USDA Fields Program funding for Project Century, one of 8 projects selected; the planned $98 million multi-year investment through 2031 is expected to add approximately 84,000 tons of annual ammonia production at Hopewell, Virginia.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, and welcome to the AdvanSix third quarter 2026 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star then two. Please note, this event is being recorded. I would now like to turn the conference over to Adam Kressel, Vice President, Investor Relations and Treasurer.
Please go ahead. Thank you, Danielle.
Good morning, and welcome to AdvanSix's third quarter 2026 earnings conference call. With me here today are President and CEO, Erin Kane, and Senior Vice President and CFO, Patrick Day. This call and webcast, including any non-GAAP reconciliations, are available on our website at investors.advansix.com. Note that elements of this presentation contain forward-looking statements that are based on our best view of the world and of our business as we see it today. Those elements can change, and the actual results could differ materially from those projected, and we ask that you consider them in that light. We refer you to the forward-looking statements included in our press release and earnings presentation. In addition, we identify the principal risks and uncertainties that affect our performance in our SEC filings, including our annual report on Form 10-K, as further updated in subsequent filings with the SEC.
This morning, we will review our financial results for the third quarter of 2026 and share our outlook for our key product lines and end markets. Finally, we will leave time for your questions at the end. With that, I will turn the call over to AdvanSix's President and CEO, Erin Kane.
Thanks, Adam, and good morning, everyone. We appreciate you joining us here today for our quarterly call. As you saw in our press release, we generated 15% sales growth year-over-year as our teams continued to leverage both formula and market-based pricing mechanisms to offset inflationary raw material costs. We also generated improved cash flow, benefiting from disciplined working capital performance and continued risk-based prioritization of base capital spending. While our core caprolactam operating rate continues to exceed global industry averages by nearly 10%, reduced production output at our Hopewell and backward-integrated Frankford manufacturing sites drove unfavorable fixed cost absorption. Patrick will dive into the financials in a moment, but I would like to start the discussion once again by framing our key strategic priorities. Our focus remains centered on the controllable levers that support through-cycle value creation, commercial execution, operational excellence, and disciplined capital deployment.
Once again, our pricing actions in aggregate nearly offset the substantial year-over-year increase in raw materials. We are maintaining margin expansion across Nylon Solutions and Chemical Intermediates. In Plant Nutrients, while we continue to navigate elevated sulfur costs, we do expect strong domestic granular ammonium sulfate volume performance for the full 2026-2027 fertilizer year. Turning to operational excellence, we are focused on supporting safe, stable, and sustainable operations while improving earnings and cash conversion through the cycle. Our approach includes risk-based capital prioritization, disciplined turnaround scoping, and the use of continuous improvement as a productivity engine across the enterprise. We continue to progress our multi-year $30 million non-manpower fixed cost reduction program and are on track for year one savings. While this year operating rates are tracking lower year-over-year, including the winter storm impacts of 1Q 2026, we have been optimizing mix across the integrated value chain.
Ammonia sales are expected to be up 25% for the full year, and our nylon resin production output is running about 5% higher year-over-year. We're both enhancing our focus in the area of reliability while continuing to enable levers to further position us for forward performance as we look to 2027. Lastly, we are focused on generating meaningful operating cash flow to support disciplined capital deployment. From a working capital perspective, our cash conversion cycle continues to benchmark in the top quartile among peers. Our significant runway of opportunity on 45Q carbon capture tax credits also supports future cash generation. We believe even through the downturn that prudently investing in the right areas for growth and performance is key to driving long-term shareholder value and is reflected in our continued advancement of the SUSTAIN program.
As we look forward, we will ensure a well-managed balance sheet as we continue to progress evaluation of our potential DEF growth project, as well as Project CENTURY. Looking ahead, we remain focused on navigating near-term market dynamics while taking deliberate actions to strengthen our performance and position AdvanSix for the future. With that, I'll turn it to Patrick to discuss the financials.
Thanks, Erin. I'm now on slide four to discuss our results for the third quarter. Sales increased 15% year-over-year to $431 million, driven by 17% favorable pricing, partially offset by a 2% decline in volume. Raw material pass-through pricing was up 10%, following a net cost increase in benzene and propylene. Market-based pricing improved 7%, reflecting increases across all product lines. As Erin highlighted earlier, we were pleased by the strong commercial execution amid a higher input cost environment. The sales volume decline was primarily driven by lower domestic and export caprolactam sales. Adjusted EBITDA was $15 million, down $10 million from last year. I will highlight the key year-over-year variances in a moment. Adjusted earnings per share loss of $0.24 declined by $0.32 versus the prior year, driven primarily by the lower EBITDA.
We expect the full year 2026 effective tax rate to be approximately 20%, in line with our year-to-date results. Cash performance improved meaningfully. Cash flow from operations was $48 million, up $21 million from the prior year, primarily reflecting working capital discipline. CapEx declined by $8 million to $18 million as planned, supporting $30 million of free cash flow generation in the quarter. Now, let's turn to slide seven. In the quarter, we drove pricing improvement across the portfolio on a year-over-year basis. This was supported by higher raw material pass-through pricing, as well as an increase in market-based pricing. Looking across the portfolio, nylon resin sales increased 33% year over year, while caprolactam sales were roughly flat. Resin volumes continued to increase on improved operational performance at Chesterfield, while domestic and export caprolactam volumes declined in a soft building and construction environment.
Consistent with our operating approach, we evaluate the optimal product and geographic mix to ensure the best economic outcome for the integrated enterprise. Plant Nutrients sales increased 8% year over year on higher pricing, while sales improved 14% sequentially. The North American ammonium sulfate fall fill program was well received with strong volume interest. However, this was partially offset by the seasonal sequential domestic pricing decline. Lastly, Chemical Intermediates sales increased 24% year over year, supported by both price and volume improvement. Sales declined sequentially on moderating propylene prices and lower acetone volume, primarily driven by timing of acetone shipments to align with end market demand. Now, let's turn to slide six. Here, we highlight the key drivers of our third quarter Adjusted EBITDA performance year over year.
As a reminder, we track three primary variable margin equations across our portfolio: caprolactam and nylon resin over benzene, acetone over propylene, and ammonium sulfate less sulfur and natural gas. Raw material costs were our largest headwind in the quarter of $65 million. This was primarily driven by rising sulfur and benzene prices, and to a lesser extent, increasing propylene prices. Natural gas prices were modestly lower year over year. We were able to more than offset the raw material impact of benzene and propylene in our Nylon Solutions and Chemical Intermediates product lines through strong commercial execution with favorable market and pass-through pricing mechanisms. In Plant Nutrients, the fall fill results, driven by both a seasonal reset and challenging competitive dynamics, impacted price over raws performance with continued sulfur cost headwinds. These dynamics also contributed to a greater than typical sequential seasonal earnings impact.
Sales volume overall represented a minor unfavorable impact to Adjusted EBITDA. SG&A contributed an approximately $3 million benefit, reflecting disciplined cost management, including our non-manpower fixed cost initiative. SG&A also benefited from the absence of the investment to upgrade our enterprise resource planning system in the prior year period. Lastly, all other items netted to an $8 million headwind, primarily due to the impact of reduced production output. As discussed earlier, the impact overall primarily reflected unfavorable fixed cost absorption. Now, let's turn to slide seven. On the left side of the page, we've shown our third quarter year-to-date free cash flow generation for 2025 and 2026. Our year-to-date performance is largely in line with last year. However, the prior year period benefited from $26 million of insurance proceeds, so we are operationally performing better on a normalized basis.
Working capital was a $24 million source of cash year to date, compared with a $56 million use of cash in the prior year period. This improvement reflects disciplined inventory optimization aligned with end market dynamics and our business rules. As an organization, we are driving meaningful working capital performance, supporting improvement in the overall cash conversion cycle. As we've shared previously, there is non-linearity in our cash flow on a quarterly basis. Looking ahead, we anticipate working capital tailwinds to continue into the fourth quarter, supported by ammonium sulfate pre-buy cash advances amid current fertilizer pricing. We now expect full year 2026 CapEx of approximately $90 million, comprised of $75 million of base capital and $15 million of high-return growth investments. Of note, we are commissioning the SUSTAIN ammonium sulfate project this quarter. The SUSTAIN program overall continues to exceed our return expectations.
Finally, our new five-year, $425 million credit facility, which successfully closed in August, now consists of a revolver and term loan at comparable terms and conditions to our previous facility. The facility provides ample liquidity for our business needs and supports capital deployment optionality. Let me turn the call back to Erin.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
6 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
